Insulin degludec and insulin degludec/insulin aspart receive positive vote for approval from FDA Advisory Committee
2012-11-08 · Novo Nordisk A/S · original novonordisk.com ↗
Bagsværd, Denmark, 9 November 2012 Novo Nordisk today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the United States Food and Drug Administration (FDA) has completed its meeting regarding the New Drug Applications (NDA) for insulin degludec and insulin degludec/insulin aspart. Further information Media: Mike Rulis +45 4442 3573 [email protected] Ambre Morley (US) +1 609 216 5240 [email protected] Investors: Kasper Roseeuw Poulsen +45 4442 4303 [email protected] Frank Daniel Mersebach +45 4442 0604 [email protected] Lars Borup Jacobsen +45 3075 3479 [email protected] Jannick Lindegaard (US) +1 609 786 4575 [email protected] Company announcement No 72 /2012
The release as fetched from its publisher. novonordisk.com ↗